Clinical Trial Update: QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial of QPI-1002 for prevention of major adverse kidney events in high-risk AKI patients after cardiac surgery was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Surgery-related Kidney Injury
• Kidney Injury

Drugs mentioned

• QPI-1002

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Cardiac Surgery | Phase 3 | Status: TERMINATED